News Valeant sells female libido drug back to former owners Valeant has sold its controversial female libido drug to former shareholders in Sprout, the company that first developed it before a $1 billion buyout two years ago.
News ESC26: Isomab safety evidence on blood vessel growth for CAD Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
